Role of muscarinic antagonists in asthma therapy

References

• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504.
   PubMed Web of Science ®Google Scholar
• Goldie RG, Spina D, Henry PJ, et al. In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline. Br J Clin Pharmacol. 1986;22(6):669–676.
   PubMed Web of Science ®Google Scholar
• Haddad EB, Mak JC, Hislop A, et al. Characterization of muscarinic receptor subtypes in pig airways: radioligand binding and northern blotting studies. Am J Physiol. 1994;266(6 Pt 1):L642–L648.
   PubMed Web of Science ®Google Scholar
• Racké K, Matthiesen S. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2004;17(4):181–198.
   PubMed Web of Science ®Google Scholar
• Sarria B, Naline E, Zhang Y, et al. Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. Am J Physiol Lung Cell Mol Physiol. 2002;283(5):L1125–L1132.
   PubMed Web of Science ®Google Scholar
• Kageyama N, Igarashi A, Ichinose M, et al. Chronic allergen exposure enhances cholinergic neurotransmission in sensitized guinea-pigs. Eur Respir J. 1995;8(5):752–754.
   PubMed Web of Science ®Google Scholar
• Meurs H, Oenema TA, Kistemaker LE, et al. A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol. 2013;13(3):316–323.
   PubMed Web of Science ®Google Scholar
• Verbout NG, Lorton JK, Jacoby DB, et al. Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1126–L1135.
   PubMed Web of Science ®Google Scholar
• Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther. 2003;98(1):59–69.
   PubMed Web of Science ®Google Scholar
• Tohda Y, Haraguchi R, Itoh M, et al. Role of muscarinic acetylcholine receptors in a guinea pig model of asthma. Int Immunopharmacol. 2002;2(11):1521–1527.
   PubMed Web of Science ®Google Scholar
• Ichinose M, Miura M, Tomaki M, et al. Incubation with IgE increases cholinergic neurotransmission in human airways in vitro. Am J Respir Crit Care Med. 1996;154:1272–1276.
   PubMed Web of Science ®Google Scholar
• Raemdonck K, De Alba J, Birrell MA, et al. A role for sensory nerves in the late asthmatic response. Thorax. 2012;67(1):19–25.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol. 2012;129(1):48–59.
   PubMed Web of Science ®Google Scholar
• Kistemaker LE, Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci. 2015;36(3):164–171.
   PubMed Web of Science ®Google Scholar
• Pieper MP. The non-neuronal cholinergic system as novel drug target in the airways. Life Sci. 2012;91(21–22):1113–1118.
   PubMed Web of Science ®Google Scholar
• Liccardi G, Salzillo A, Calzetta L, et al. Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. Respir Med. 2016;117:150–153.
   PubMed Web of Science ®Google Scholar
• Goyal M, Jaseja H, Verma N. Increased parasympathetic tone as the underlying cause of asthma: a hypothesis. Med Hypotheses. 2010;74(4):661–664.
   PubMed Web of Science ®Google Scholar
• Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med. 2013 Oct;1(8):639–652.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Centanni S, Donner CF. Anticholinergic agents. Pulm Pharmacol Ther. 1998;11(5–6):381–392.
   Web of Science ®Google Scholar
• Ihre E, Larsson K. Airways responses to ipratropium bromide do not vary with time in asthmatic subjects. Studies of interindividual and intraindividual variation of bronchodilatation and protection against histamine-induced bronchoconstriction. Chest. 1990;97(1):46–51.
   PubMed Web of Science ®Google Scholar
• Ward MJ, Fentem PH, Smith WH, et al. Ipratropium bromide in acute asthma. Br Med J (Clin Res Ed). 1981;282:598–600.
   PubMed Web of Science ®Google Scholar
• Sheppard D, Epstein J, Holtzman M, et al. Dose-dependent inhibition of cold air-induced bronchoconstriction by atropine. Respir Environ Exerc Physiol. 1982;53:169–174.
   PubMed Web of Science ®Google Scholar
• Fryer AD, Jacoby DB. Cholinergic mechanisms and anticholinergic therapy in respiratory diseases. In: Adkinson NF Jr, Busse WW, Bochner BS, et al., eds. Middleton’s allergy: principles and practice. 7th ed. Philadelphia, PA: Elsevier; 2008. p. 1603–1618.
   Google Scholar
• Jolobe OM. Asthma vs. non-specific reversible airflow obstruction: clinical features and responsiveness to anticholinergic drugs. Respiration. 1984;45(3):237–242.
   PubMed Web of Science ®Google Scholar
• Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006;533:36–39.
   PubMed Web of Science ®Google Scholar
• Ullah MI, Newman GB, Saunders KB. Influence of age on response to ipratropium and salbutamol in asthma. Thorax. 1981;36:523–529.
   PubMed Web of Science ®Google Scholar
• Lougheed MD, Lemiere C, Dell SD, et al. Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for children six years of age and over, and adults. Can Respir J. 2010;17:15–24.
   PubMed Web of Science ®Google Scholar
• Van Schayck CP, Folgering H, Harbers H, et al. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma. Thorax. 1991;46:355–359.
   PubMed Web of Science ®Google Scholar
• McDonald NJ, Bara AI. Anticholinergic therapy for chronic asthma in children over two years of age. Cochrane Database Syst Rev. 2003;(3):CD003535.
   Google Scholar
• Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev. 2004;(3):CD003269.
   Google Scholar
• Adimadhyam S, Schumock GT, Walton S, et al. Risk of arrhythmias associated with ipratropium bromide in children, adolescents, and young adults with asthma: a nested case-control study. Pharmacotherapy. 2014;34(4):315–323.
   PubMed Web of Science ®Google Scholar
• Ringbaek T, Viskum K. Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma? Respir Med. 2003;97(3):264–272.
   PubMed Web of Science ®Google Scholar
• Ward MJ, Fentem PH, Smith WH, et al. Ipratropium bromide in acute asthma. Br Med J. 1981;282:598–600.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Wise R, Busse WW, et al. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. BMC Pulm Med. 2016;16(1):65.
   PubMed Web of Science ®Google Scholar
• Garrett JE. Combined anticholinergic therapy in the management of acute asthma. Respirology. 1997;2(Suppl 1):S17–S18.
   PubMedGoogle Scholar
• Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med. 2000;161(6):1862–1868.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. Chest. 2003;123(6):1908–1915.
   PubMed Web of Science ®Google Scholar
• Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized ipratropium in severely asthmatic children. Ann Emerg Med. 1997;29(2):205–211.
   PubMed Web of Science ®Google Scholar
• Qureshi F, Pestian J, Davis P, et al. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med. 1998;339(15):1030–1035.
   PubMed Web of Science ®Google Scholar
• Goggin N, Macarthur C, Parkin PC. Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. Arch Pediatr Adolesc Med. 2001;155:1329–1334.
   PubMedGoogle Scholar
• Memon BN, Parkash A, Ahmed Khan KM, et al. Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. J Pak Med Assoc. 2016;66(3):243–246.
   PubMed Web of Science ®Google Scholar
• Plotnick LH, Ducharme FM. Should inhaled anticholinergics be added to β2 agonists for treating acute childhood and adolescent asthma? A systematic review. Bmj. 1998;317:971–977.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005;60:740–746.
   PubMed Web of Science ®Google Scholar
• Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta2-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database Syst Rev. 2014;(7):CD010283.
   Google Scholar
• Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2013;(8):CD000060.
   Google Scholar
• Wyatt EL, Borland ML, Doyle SK, et al. Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: A single-blinded randomised controlled trial. J Paediatr Child Health. 2015;51(2):192–198.
   PubMed Web of Science ®Google Scholar
• Buels KS, Jacoby DB, Fryer AD. Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of allergic asthma. Br J Pharmacol. 2012;165(5):1501–1514.
   PubMed Web of Science ®Google Scholar
• Bosnjak B, Tilp C, Tomsic C, et al. Tiotropium bromide inhibits relapsing allergic asthma in BALB/c mice. Pulm Pharmacol Ther. 2014;27(1):44–51.
   PubMed Web of Science ®Google Scholar
• Gosens R, Bos IS, Zaagsma J, et al. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med. 2005;171(10):1096–1102.
   PubMed Web of Science ®Google Scholar
• Bos IS, Gosens R, Zuidhof AB, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J. 2007;30(4):653–661.
   PubMed Web of Science ®Google Scholar
• Kang JY, Rhee CK, Kim JS, et al. Effect of tiotropium bromide on airway remodeling in a chronic asthma model. Ann Allergy Asthma Immunol. 2012;109(1):29–35.
   PubMed Web of Science ®Google Scholar
• Ohta S, Oda N, Yokoe T, et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy. 2010;40(8):1266–1275.
   PubMed Web of Science ®Google Scholar
• Damera G, Jiang M, Zhao H, et al. Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation. Eur J Pharmacol. 2010;649(1–3):349–353.
   PubMed Web of Science ®Google Scholar
• Kistemaker LE, Bos IS, Menzen MH, et al. Combination therapy of tiotropium and ciclesonide attenuates airway inflammation and remodeling in a guinea pig model of chronic asthma. Respir Res. 2016;17:13.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm Pharmacol Ther. 2016;36:1–9.
   PubMed Web of Science ®Google Scholar
• Johnson BE, Suratt PM, Gal TJ, et al. Effect of inhaled glycopyrrolate and atropine in asthma. Precipitated by exercise and cold air inhalation. Chest. 1984;85(3):325–328.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest. 2005;128(4):1974–1979.
   PubMed Web of Science ®Google Scholar
• O’Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med. 1996;154(4 Pt 1):876–880.
   PubMed Web of Science ®Google Scholar
• Terzano C, Petroianni A, Ricci A, et al. Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev Med Pharmacol Sci. 2004;8(6):259–264.
   PubMedGoogle Scholar
• Sposato B, Calabrese A, Barzan R, et al. Comparison of the protective effect amongst anticholinergic drugs on methacholine-induced bronchoconstriction in asthma. J Asthma. 2008;45(5):397–401.
   PubMed Web of Science ®Google Scholar
• Short P, Williamson P, Anderson W, et al. Randomised placebo controlled trial to evaluate chronic dosing effects of propranolol in steroid treated persistent asthmatics [abstract]. Thorax. 2012;67:A68.
   Web of Science ®Google Scholar
• Gilman MJ, Meyer L, Carter J, et al. Comparison of aerosolized glycopyrrolate and metaproterenol in acute asthma. Chest. 1990;98(5):1095–1098.
   PubMed Web of Science ®Google Scholar
• Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma. Ann Emerg Med. 1994;23(2):270–274.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Bugnas B, Van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008;102(1):50–56.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Nakano T, Fukuyama S, et al. Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes. Pulm Pharmacol Ther. 2013;26(2):159–166.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kaneko Y, Ishimatsu A, et al. Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma. Pulm Pharmacol Ther. 2017;42:7–12.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Kirsten AM, Dusser D, et al. Pharmacodynamics and pharmacokinetics following once-daily and twice-daily dosing of tiotropium Respimat® in asthma using standardized sample-contamination avoidance. J Aerosol Med Pulm Drug Deliv. 2016;29(5):406–415.
   PubMed Web of Science ®Google Scholar
• Timmer W, Moroni-Zentgraf P, Cornelissen P, et al. Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Respir Med. 2015;109(3):329–338.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Engel M, Moroni-Zentgraf P, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir Med. 2014;108(9):1268–1276.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, et al. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Respir Res. 2015;16:20.
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Yokoyama A, Shiota N, et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J. 2008;31(6):1379–1380.
   PubMed Web of Science ®Google Scholar
• Park HW, Yang MS, Park CS, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009;64(5):778–783.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128(2):315–322.
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363(18):1715–1726.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Disse B, Schröder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128(2):308–314.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367–376.
   PubMed Web of Science ®Google Scholar
• Paggiaro P, Halpin DM, Buhl R, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: A randomized controlled trial. J Allergy Clin Immunol Pract. 2016;4(1):104–113.e2.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Yawn BP, Fuhlbrigge AL, et al. Anticholinergic vs long-acting β-agonist in combination with inhaled corticosteroids in Black adults with asthma: the BELT randomized clinical trial. Jama. 2015;314(16):1720–1730.
   PubMed Web of Science ®Google Scholar
• Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium Respimat® Is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: A randomised, placebo-controlled study. Plos One. 2015;10(4):e0124109.
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Bateman ED, Vogelberg C, et al. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. J Allergy Clin Immunol. 2016;138(2):441–450.
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Bernstein JA, Vandewalker M, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49(1):1601100.
   PubMed Web of Science ®Google Scholar
• Huang J, Chen Y, Long Z, et al. Clinical efficacy of tiotropium in children with asthma. Pak J Med Sci. 2016;32(2):462–465.
   PubMed Web of Science ®Google Scholar
• Fardon T, Haggart K, Lee DKC, et al. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med. 2007;101(6):1218–1228.
   PubMed Web of Science ®Google Scholar
• Rider NL, Craig TJ. A safety review of long-acting β2-agonists in patients with asthma. J Am Osteopath Assoc. 2006;106(9):562–567.
   PubMedGoogle Scholar
• Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled crossover trial. Lancet. 2004;364(9444):1505–1512.
   PubMed Web of Science ®Google Scholar
• Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol. 2007;119(6):1337–1348.
   PubMed Web of Science ®Google Scholar
• Peters SP, Bleecker ER, Kunselman SJ, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol. 2013;132(5):1068–1074.e1.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Sanduzzi A, et al. Influence of ethnicity on response to asthma drugs. Expert Opin Drug Metab Toxicol. 2015 l;11(7):1089–1097.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodríguez JA. What is the role of tiotropium in asthma?: A systematic review with meta-analysis. Chest. 2015;147(2):388–396.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodríguez JA. Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2015;115(3):211–216.
   PubMed Web of Science ®Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016 1;(1):CD011721.
   Google Scholar
• Lou LL, Gong HH, Zhang MQ, et al. Efficacy and safety of tiotropium in the treatment of severe persistent asthma: meta-analysis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016;38(1):62–68.
   PubMedGoogle Scholar
• Walker FB 4th, Kaiser DL, Kowal MB, et al. Prolonged effect of inhaled glycopyrrolate in asthma. Chest. 1987;91(1):49–51.
   PubMed Web of Science ®Google Scholar
• Schroeckenstein DC, Bush RK, Chervinsky P, et al. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol. 1988;82(1):115–119.
   PubMed Web of Science ®Google Scholar
• Lee LA, Briggs A, Edwards LD, et al. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma. Respir Med. 2015;109(1):63–73.
   PubMed Web of Science ®Google Scholar
• Lee LA, Yang S, Kerwin E, et al. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med. 2015;109(1):54–62.
   PubMed Web of Science ®Google Scholar
• Lee L, Kerwin K, Collison K, et al. Umeclidinium dose-response in patients with fixed airflow obstruction and reversibility to albuterol irrespective of a primary diagnosis of asthma or COPD [abstract]. Am J Respir Crit Care Med. 2016;193:A6831.
   Web of Science ®Google Scholar
• Yang S, Goyal N, Beerahee M, et al. Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma. Eur J Clin Pharmacol. 2015;71(9):1051–1058.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. P/0005/2015. [ cited 2016 Nov 9]. Avalaible from: http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500183847.pdf
   Google Scholar
• Chin SJ, Durmowicz AG, Chowdhury BA. Tiotropium Respimat is effective for the treatment of asthma at a dose lower than that for chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2016;13(2):173–179.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. 2016 GINA Report, Global Strategy for Asthma Management and Prevention.[cited 2016 Nov 9] Avalaible from: http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/.
   Google Scholar
• Kew KM, Evans DJ, Allison DE, et al. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev. 2015 Jun 2;(6):CD011438.
   Google Scholar
• Bobolea ID, Melero C, Jurado-Palomo J. Current and future asthma treatments: phenotypical approach on the path to personalized medicine in asthma. In: Pereira C, ed. Asthma - From Childhood Asthma to ACOS Phenotypes. Rijeka, Croazia: Intech; 2016. p. 115–135.
   Google Scholar
• Perpiña M. Anticolinergicos en el asma. Espacio Asma. 2011;4(3):70–75.
   Google Scholar
• Bateman ED, Rennard S, Barnes PJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol. 2009;22(6):533–542.
   Google Scholar